Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892678 · ClinicalTrials.gov registry record · Phase 1
DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
A Phase 1 study of Osteosarcoma Recurrent and Ewing's Tumor Recurrent, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06892678: Recruiting Phase 1 study of Osteosarcoma Recurrent and Ewing's Tumor Recurrent, sponsored by Montefiore Medical Center.
NCT06892678 is a Phase 1 study of Osteosarcoma Recurrent and Ewing's Tumor Recurrent that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 15 participants, below the 39-participant average among 4 other Osteosarcoma Recurrent trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06892678, a Phase 1 study of Osteosarcoma Recurrent and Ewing's Tumor Recurrent, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the feasibility of administering DFMO to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.
Primary Outcome
Feasibility will be defined as the ability to successfully administer DFMO to at least 80% of subjects who initiate therapy until either disease recurrence or completion of the maximally allowed duration of therapy. Results will be summarized using basic descriptive statistics.
Conditions Studied
Interventions
- DRUG DFMO
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2030-04 |
| Phase | Phase 1 |
What NCT06892678 shows while recruiting
NCT06892678 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 39-participant average among 4 other Osteosarcoma Recurrent trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Osteosarcoma Recurrent appearing as the primary indexed condition, and to 1 intervention - of which DFMO is the first listed.
NCT06892678 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06892678 about?
NCT06892678 is a clinical study titled "DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma". The purpose of this study is to determine the feasibility of administering DFMO to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.
What is the current status of trial NCT06892678?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-04-07. Estimated completion is 2030-04.
What conditions does trial NCT06892678 study?
This clinical trial studies the following conditions: Osteosarcoma Recurrent, Ewing's Tumor Recurrent.
What interventions are being tested in trial NCT06892678?
The interventions under investigation include: DFMO (DRUG).
Who is sponsoring clinical trial NCT06892678?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06892678 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
RECRUITING · Phase 1
-
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
ACTIVE NOT RECRUITING · Phase 1
-
Olaparib With Ceralasertib in Recurrent Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI